KI
LVTX

Kapitalo Investimentos’s LAVA Therapeutics LVTX Stock Holding History

Kapitalo Investimentos’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,200
Closed -$74.2K – 471
2022
Q4 		$74.2K Buy
+21,200
New +$97.3K 0.06% 111

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kapitalo Investimentos's LVTX Position: Q1 2023 in Review

Kapitalo Investimentos sold out of LAVA Therapeutics (LVTX) in Q1 2023, closing a stake of 21,200 shares — an estimated $74.2K sold.

Kapitalo Investimentos first reported a position in LVTX in Q4 2022 and held it in 1 quarter. The position peaked at $74.2K in Q4 2022. 19 funds tracked by Wall St. Rank hold LVTX as of Q1 2023.

  • Kapitalo Investimentos reported no remaining LAVA Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Kapitalo Investimentos sold 21,200 LAVA Therapeutics shares in Q1 2023, an estimated $74.2K.
  • Kapitalo Investimentos first reported a position in LAVA Therapeutics in Q4 2022 and held it in 1 quarter.
  • Kapitalo Investimentos's LAVA Therapeutics position peaked at $74.2K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2023.

Based on Kapitalo Investimentos's 13F filing for Q1 2023, filed 29 Mar 2024.